Arbuckle Stuart A

Arbuckle Stuart A, EVP and COO, has demonstrated a clear selling bias in recent insider transactions, with $39.4 million in total sales compared to just $13,105 in purchases across 34 reported trades involving four companies. The bulk of this activity has centered on Vertex Pharmaceuticals (VRTX), where multiple high-value sales occurred between February 2024 and July 2025. Notably, on July 1, 2025, Arbuckle sold $16.8 million worth of VRTX shares, followed by earlier dispositions of $3.4 million and $2.3 million in late February 2025. The pattern extends to 2024, with five VRTX sales exceeding $1 million each in February alone, including a $2 million transaction on February 26 and a $2 million derivative disposition on February 23. More recent filings show activity in Praxis Precision Medicines (PRAX) and Alnylam Pharmaceuticals (ALNY), though these involved non-monetary awards rather than open-market transactions. Arbuckle’s trading history also includes derivative transactions and dispositions related to ImmunoGen (IMGN) in February 2024, though these carried no reported dollar value. The absence of any recent purchases—coupled with the scale and consistency of sales, particularly in VRTX—suggests a prolonged unwinding of positions rather than short-term profit-taking. The transactions reflect a focus on biopharmaceutical holdings, with VRTX dominating both the frequency and monetary weight of the activity.